<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3010222835
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TREZOL 2.5 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LETROZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        165.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LABORATORIOS CINFA SA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BG04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Trezol is and how it works</p><p>Trezol contains an active substance called letrozole. It belongs to a group of medicines called aromatase inhibitors. It is a hormonal (or &ldquo;endocrine&rdquo;) breast cancer treatment. Growth of breast cancer is frequently stimulated by oestrogens which are female sex hormones. Trezol reduces the amount of oestrogen by blocking an enzyme (&ldquo;aromatase&rdquo;) involved in the production of oestrogens and therefore may block the growth of breast cancer that needs oestrogens to grow. As a consequence tumour cells slow or stop growing and/or spreading to other parts of the body.</p><p>&nbsp;</p><p>What Trezol is used for</p><p>Trezol is used to treat breast cancer in women who have gone through menopause i.e cessation of periods.</p><p>&nbsp;</p><p>It is used to prevent cancer from happening again. It can be used as first treatment before breast cancer surgery in case immediate surgery is not suitable or it can be used as first treatment after breast cancer surgery or following five years treatment with tamoxifen. Trezol is also used to prevent breast tumour spreading to other parts of the body in patients with advanced breast cancer.</p><p>&nbsp;</p><p>If you have any questions about how Trezol works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all the doctor&rsquo;s instructions carefully. They may differ from the general information in this leaflet.</p><p>&nbsp;</p><p>Do not take Trezol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to letrozole or to any of the other ingredients of this medicine (listed in section 6),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you still have periods, i.e. if you have not yet gone through the menopause,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding.</p><p>If any of these conditions apply to you<strong>,</strong><strong> </strong><strong>do</strong><strong> </strong><strong>not</strong><strong> </strong><strong>take</strong><strong> </strong><strong>this</strong><strong> </strong><strong>medicine</strong><strong> </strong><strong>and</strong><strong> </strong><strong>talk</strong><strong> </strong><strong>to</strong><strong> </strong><strong>your</strong><strong> </strong><strong>doctor.</strong></p><p><strong>&nbsp;</strong></p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Trezol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe kidney disease,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe liver disease,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of osteoporosis or bone fractures (see also &ldquo;Follow-up during Trezol treatment&rdquo; in section 3).</p><p>If any of these conditions apply to you, <strong>tell</strong><strong> </strong><strong>your</strong><strong> </strong><strong>doctor</strong>. Your doctor will take this into account during your treatment with Trezol.</p><p>&nbsp;</p><p>Children and adolescents (below 18 years)</p><p>Children and adolescents should not use this medicine.</p><p>&nbsp;</p><p>Older people (age 65 years and over)</p><p>People aged 65 years and over can use this medicine at the same dose as for other adults.</p><p>&nbsp;</p><p>Other medicines and Trezol</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should only take Trezol when you have gone through the menopause. However, your doctor should discuss with you the use of effective contraception, as you may still have the potential to become pregnant during treatment with Trezol.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must not take Trezol if you are pregnant or breast feeding as it may harm your baby.</p><p>&nbsp;</p><p>Driving and using machines</p><p>If you feel dizzy, tired, drowsy or generally unwell, do not drive or operate any tools or machines until you feel normal again.</p><p>&nbsp;</p><p>Trezol contains lactose</p><p>Trezol contains lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The usual dose is one tablet of Trezol to be taken once a day. Taking Trezol at the same time each day will help you remember when to take your tablet.</p><p>&nbsp;</p><p>The tablet can be taken with or without food and should be swallowed whole with a glass of water or another liquid.</p><p>&nbsp;</p><p>How long to take Trezol</p><p>Continue taking Trezol every day for as long as your doctor tells you. You may need to take it for months or even years. If you have any questions about how long to keep taking Trezol, talk to your doctor.</p><p>&nbsp;</p><p>Follow-up during Trezol treatment</p><p>You should only take this medicine under strict medical supervision. Your doctor will regularly monitor your condition to check whether the treatment is having the right effect.</p><p>&nbsp;</p><p>Letrozole may cause thinning or wasting of your bones (osteoporosis) due to the reduction of oestrogens in your body. Your doctor may decide to measure your bone density (a way of monitoring for osteoporosis) before, during and after treatment.</p><p>&nbsp;</p><p>If you take more Trezol than you should</p><p>If you have taken too much Trezol, or if someone else accidentally takes your tablets, contact a doctor or hospital for advice immediately. Show them the pack of tablets. Medical treatment may be necessary.</p><p>&nbsp;</p><p>If you forget to take Trezol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If it is almost time for your next dose (e.g. within 2 or 3 hours), skip the dose you missed and take your next dose when you are meant to.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Otherwise, take the dose as soon as your remember, and then take the next tablet as you would normally.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for the one that you missed.</p><p>&nbsp;</p><p>If you stop taking Trezol</p><p>Do not stop taking Trezol unless your doctor tells you to. See also the section above &ldquo;How long to take Trezol&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment.</p><p>&nbsp;</p><p>Some of these side effects, such as hot flushes, hair loss or vaginal bleeding, may be due to the lack of oestrogens in your body.</p><p>&nbsp;</p><p>Do not be alarmed by this list of possible side effects. You may not experience any of them.</p><p>&nbsp;</p><p><strong>Some side effects could be serious: Uncommon </strong>(may affect up to 1 in 100 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness, paralysis or loss of feeling in any part of the body (particularly arm or leg), loss of coordination, nausea, or difficulty speaking or breathing (sign of a brain disorder, e.g. stroke).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden oppressive chest pain (sign of a heart disorder).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling and redness along a vein which is extremely tender and possibly painful when touched.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe fever, chills or mouth ulcers due to infections (lack of white blood cells).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe persistent blurred vision.</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing, chest pain, fainting, rapid heart rate, bluish skin discoloration, or sudden arm, leg or foot pain (signs that a blood clot may have formed).</p><p>&nbsp;</p><p>If any of the above occurs, tell your doctor straight away.</p><p><strong>&nbsp;</strong></p><p>You should also inform the doctor straight away if you experience any of the following symptoms during treatment with letrozole:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling mainly of the face and throat (signs of allergic reaction).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow skin and eyes, nausea, loss of appetite, dark-coloured urine (signs of hepatitis).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (signs of skin disorder).</p><p>&nbsp;</p><p><strong>Some side effects are very common </strong>(may affect more than 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flushes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased level of cholesterol (hypercholesterolaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased sweating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in bones and joints (arthralgia)</p><p>If any of these affects you severely, tell your doctor.</p><p>&nbsp;</p><p><strong>Some side effects are common (</strong>may affect up to 1 in 10 people)<strong>:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malaise (generally feeling unwell)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal disorders such as nausea, vomiting, indigestion, constipation, diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in or loss of appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in muscles</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thinning or wasting of your bones (osteoporosis), leading to bone fractures in some cases (see also &ldquo;Follow-up during Trezol treatment&rdquo; in section 3)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of arms, hands, feet, ankles (oedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight increase</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised blood pressure (hypertension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations, rapid heart rate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint stiffness (arthritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain</p><p>If any of these affects you severely, tell your doctor.</p><p>&nbsp;</p><p><strong>Other</strong><strong> side effects are uncommon (</strong>may affect up to 1 in 100 people)<strong>:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervous disorders such as anxiety, nervousness, irritability, drowsiness, memory problems, somnolence, insomnia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain or burning sensation in the hands or wrist (carpal tunnel syndrome)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impairment of sensation, especially that of touch</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye disorders such as blurred vision, eye irritation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin disorders such as itching (urticaria)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal discharge or dryness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thirst, taste disorder, dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dryness of mucous membranes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight decrease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection, increased frequency of urination</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased level of enzymes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of the skin and eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood levels of bilirubin (a breakdown product of red blood cells)</p><p>&nbsp;</p><p><strong>Side effects with frequency not known </strong>(frequency cannot be estimated from the available data)</p><p>Trigger finger, a condition in which your finger or thumb catches in bent position. If any of these affects you severely, tell your doctor.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Trezol after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&ordm;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use any pack that is damaged or shows signs of tampering.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is letrozole. Each film-coated tablet contains 2.5 mg letrozole.</p><p>The other ingredients of the tablet core are: lactose monohydrate, sodium carboxymethyl starch, microcrystalline cellulose, hypromellose, anhydrous colloidal silica and magnesium stearate.</p><p>The ingredients of the tablet coating, Opadry Yellow, are: hypromellose, macrogol 6000, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172) and tartrazine (E102).</p><p><br />&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Trezol is supplied as yellow, circular, biconvex, film coated tablets plain on both sides and with printed code (L) in one side.

Trezol is supplied in packages containing 30 tablets (in 10 tablets blister-packs).




            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>LABORATORIOS CINFA, S.A.</p><p>Olaz-Chipi, 10 &ndash; Pol&iacute;gono Industrial Areta</p><p>31620 Huarte (Navarra)</p><p>Spain</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 09/2017.

 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي تريزول على مادة فعالة تُدعى ليتروزول. وينتمي إلى مجموعة من الأدوية تعرف بمثبطات الأروماتيز. وهو علاج هرموني</p><p dir="RTL">لعلاج سرطان الثدي. تعمل الإستروجينات وهي هرمونات جنسية أنثوية على تحفيز نمو سرطان الثدي. تريزول يعمل على خفض</p><p dir="RTL">كمية هرمون الإستروجين من خلال تثبيط عمل إنزيم (&quot;أروماتيز&quot;) المحفز لعملية إفراز الإستروجينات مما يؤدي بدوره إلى وقف نمو</p><p dir="RTL">سرطان الثدي الذي يحتاج إلى الإستروجينات للنمو. وبالتالي تنمو الخلايا السرطانية ببطء أو تتوقف عن النمو و/أو الانتشار في أجزاء</p><p dir="RTL">أخرى من الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ماهي دواعي استعمال </strong><strong>تريزول</strong></p><p dir="RTL">يُستخدم تريزول لعلاج سرطان الثدي لدى النساء اللاتي وصلن الى سن انقطاع الطمث؛ أي توقف نزول الدورة الشهرية.</p><p dir="RTL">يُستخدم في الوقاية من الإصابة بالسرطان مرة اخرى. يمكن استخدامه كعلاج أولي قبل إجراء جراحة لإزالة ورم فى الثدي في حال عدم</p><p dir="RTL">إمكانية إجراء عملية جراحية على الفور أو يمكن استخدامه كعلاج أولي بعد الجراحة أو بعد فترة علاج بتاموكسيفن امتدت لمدة 5</p><p dir="RTL">سنوات. يُستخدم أيضاً للوقاية من انتشار الورم السرطاني من الثدي الى أجزاء أخرى من الجسم في المريضات اللاتي يعانين مرحلة</p><p dir="RTL">متقدمة من سرطان الثدي.</p><p dir="RTL">إذا كان لديكِ أي أسئلة عن كيفية عمل تريزول أو لماذا وصف لك العلاج به، فسألي طبيبك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبعي جميع تعليمات الطبيب بعناية. فقد تختلف عن المعلومات العامة الواردة في هذه النشرة.</p><p dir="RTL"><strong>لا تتناولي </strong><strong>تريزول</strong><strong>:</strong></p><p dir="RTL">- إذا كان لديك حساسية لليتروزول أو أي من مكونات الدواء (المدرجة في قسم 6).</p><p dir="RTL">- إذا &nbsp;كنتِ لا تزالين في مرحلة نزول الدورة الشهرية ولم تَصلي إلى سن انقطاع الطمث.</p><p dir="RTL">- إذا كنتِ حاملاً.</p><p dir="RTL">-إذا كنتِ في فترة الإرضاع.</p><p dir="RTL">إذا انطبقت عليكِ أيٌّ من الحالات السابقة، <strong>فلا تتناولي هذا الدواء واستشيري الطبيب</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدثي إلى طبيبك أو الصيدلي قبل تناول تريزول</p><p dir="RTL">- إذا كنت تعانين مرضاً شديداً في الكُلى.</p><p dir="RTL">- إذا كنت تعانين مرضاً شديداً في الكبد.</p><p dir="RTL">- إذا كان لديك تاريخ مَرضي بالإصابة بهشاشة العظام أو الكسور (انظري &quot;المتابعة خلال العلاج بتريزول &quot; في قسم 3).</p><p dir="RTL">إذا انطبقت عليك أيٌ من الحالات السابقة <strong>فاستشيري الطبيب</strong>. سيأخذ طبيبك هذا الأمر في الاعتبار خلال فترة علاجك بتريزول.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون (أقل من 18 عاماً)</strong></p><p dir="RTL">يجب على الأطفال والمراهقين عدم استخدام هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأشخاص الأكبر سناً (65 عاماً فأكثر)</strong></p><p dir="RTL">يمكن للأشخاص البالغين 65 عاماً فأكثر استخدام هذا الدواء بنفس الجرعة الموصى بها للبالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التفاعلات مع الأدوية الأخرى</strong></p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي إذا كنت تتناولين أو قد تتناولين أدوية أخرى بما في ذلك الأدوية التي يمكن الحصول عليها دون</p><p dir="RTL">وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع والخصوبة</strong></p><p dir="RTL">- يجب تناول تريزول فقط بعد وصولك سن انقطاع الطمث. بالرغم من ذلك، يجب على طبيبك التحدث معك بشأن استخدام وسيلة</p><p dir="RTL">منع الحمل فعالة، فربما يكون لا يزال لديك فرصة للحمل خلال فترة العلاج بتريزول.</p><p dir="RTL">- يجب عليكِ عدم تناول تريزول إذا كنتِ حاملاً أو في فترة الإرضاع فقد يسبب ضرراً لطفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL">في حال الشعور بالدوار، الإجهاد، الدوخة أو الإعياء العام، تجنبي القيادة أو تشغيل أي أجهزة أو آلات حتى تشعري بتحسن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوى </strong><strong>تريزول</strong><strong> </strong><strong>على اللاكتوز</strong></p><p dir="RTL">يحتوي تريزول على اللاكتوز (سكر الحليب). إذا أخبرك طبيبك بأنك تعانين حساسية لبعض أنواع السكر فاستشيري طبيبك قبل تناول</p><p dir="RTL">هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماَ تناولي هذا الدواء تماماَ حسب وصف الطبيب أو الصيدلي. استشيري طبيبك أو الصيدلي إذا لم تكوني متأكدة.</p><p dir="RTL">الجرعة العادية هي قرص واحد يومياً من تريزول. سيساعدك تناول تريزول في نفس الوقت كل يوم في تذكر وقت تناول دوائك.</p><p dir="RTL">يمكن تناول قرص الدواء مع الطعام أو بدونه ويجب بلعه بالكامل بكوب من الماء أو أي سوائل أخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مدة العلاج ب</strong><strong>تريزول</strong></p><p dir="RTL">واصلي العلاج بتريزول يومياً طوال المدة التي يخبرك بها الطبيب. قد تحتاجين إلى تناوله لمدة شهور أو حتى سنوات. إذا كان لديك</p><p dir="RTL">أي أسئلة حول مدة علاجك بتريزول فتحدثي مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المتابعة خلال فترة العلاج ب</strong><strong>تريزول</strong></p><p dir="RTL">يجب تناول هذا الدواء فقط تحت إشراف طبي دقيق. سيقوم طبيبك بمراقبة حالتك بانتظام ليتأكد من نجاح الدواء في إحداث المفعول</p><p dir="RTL">المطلوب.</p><p dir="RTL">قد يتسبب تريزول في خفض كثافة العظم ونحافته (هشاشة العظام) نتيجة لانخفاض نسبة الإستروجينات في جسمك. قد يقرر طبيبك</p><p dir="RTL">قياس كثافة عظمك (وسيلة مراقبة مرض هشاشة العظام) قبل العلاج وخلاله وبعد الانتهاء منه.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما يجب عليك القيام به عند تناول جرعة زائدة من </strong><strong>تريزول</strong></p><p dir="RTL">إذا تناولتِ جرعة زائدة من تريزول ، أو إذا تناول شخص ما الدواء عن طريق الخطأ، فاتصلي بالطبيب أو المستشفى على الفور</p><p dir="RTL">للحصول على استشارة. أظهري لهم علبة الدواء. قد تحتاجين إلى علاج طبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيتِ تناول </strong><strong>تريزول</strong></p><p dir="RTL">- إذا كان وقت الجرعة التالية قد حان (أي خلال 2 أو 3 ساعات)، فلا تتناولي الجرعة الفائتة وتناولي الجرعة التالية في وقتها المحدد.</p><p dir="RTL">- خلاف ذلك، تناولي الجرعة وقتما تتذكرين ثم تناولي القرص التالي في موعده الطبيعي.</p><p dir="RTL">- لا تتناولي جرعة مضاعفة لتعويض الجرعة الفائتة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفتى عن تناول </strong><strong>تريزول</strong></p><p dir="RTL">لا تتوقفي عن تناول تريزول حتى يخبرك الطبيب بذلك. انظري القسم الوارد أعلاه بعنوان &quot;مدة العلاج بتريزول &quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب هذا الدواء آثاراً جانبية، ولكنها لا تظهر بالضرورة على كل من يتناوله.</p><p dir="RTL">تتراوح أغلب الآثار الجانبية بين الخفيفة والمعتدلة وستختفي بوجه عام بعد العلاج بأيام قليلة وحتى أسابيع قليلة.</p><p dir="RTL">قد تحدث بعض هذه الآثار الجانبية، مثل الشعور المفاجىء بالسخونة (الهبات الساخنة) أو تساقط الشعر أو النزيف المهبلي نتيجة</p><p dir="RTL">لنقص الإستروجينات في الجسم.</p><p dir="RTL">لا تلقي بالاً إلى هذه القائمة الموضحة للآثار الجانبية. فقد لا تظهر عليك أي منها.</p><p dir="RTL"><strong>قد تكون بعض الآثار الجانبية خطيرة: غير شائعة</strong> (قد تؤثر في مريض واحد من 100 مريض):</p><p dir="RTL">- ضعف أو شلل أو فقدان الإحساس في أي جزء من أجزاء الجسم (وبخاصة الذراع أو الساق)، فقدان التنسيق الحركي، غثيان، صعوبة في الكلام أو التنفس (علامة على وجود إضطراب في المخ، مثل السكتة).</p><p dir="RTL">- ألم شديد مفاجئ في الصدر (علامة على وجود إضطراب في القلب).</p><p dir="RTL">- تورم واحمرار بطول الوريد والذي يصبح شديد الحساسية يمكن ان يكون مؤلماَ عند اللمس.</p><p dir="RTL">- حمى شديدة أو قشعريرة أو قرح في الفم نتيجة للعدوى (نقص عدد خلايا الدم البيضاء).</p><p dir="RTL">- عدم وضوح الرؤية الشديد والمستمر.</p><p dir="RTL"><strong>نادرةالحدوث (</strong>قد تؤثر في مريض واحد من 1000 مريض):</p><p dir="RTL">- صعوبة التنفس أو ألم في الصدر أو إغماء أو ضربات قلب سريعة أو تغير لون الجلد إلى الأزرق أو ألم مفاجئ في الذراع أو الساق</p><p dir="RTL">أو القدم (علامات على احتمال تكون جلطة في الدم).</p><p dir="RTL"><strong>في حال حدوث أيٍّ من الأعراض السابقة، أخبري طبيبك على الفور.</strong></p><p dir="RTL">يجب أيضاً إخبار طبيبك على الفور في حال إصابتك بأيٍّ من الأعراض التالية خلال فترة العلاج بتريزول:</p><p dir="RTL">- تورم وخاصة في الوجه والحلق (علامات حدوث تفاعل حساسية).</p><p dir="RTL">-اصفرار الجلد والعينين، غثيان، فقدان الشهية، بول غامق اللون (علامات مرض التهاب الكبد).</p><p dir="RTL">- طفح جلدي، احمرار الجلد، ظهور بثور في الشفتين أو العينين أو الفم، تقشر الجلد، حمى (علامات مرض الجلد).</p><p dir="RTL"><strong>بعض الآثار الجانبية الشائعة جدا</strong><strong>ً</strong><strong> (</strong>قد تؤثر في أكثر من مريض واحد من كل 10 مرضى):</p><p dir="RTL">- الشعور المفاجىء بالسخونة</p><p dir="RTL">- ارتفاع مستوى الكوليسترول (زيادة نسبة الكوليسترول في الدم)</p><p dir="RTL">- الشعور بالإجهاد</p><p dir="RTL">- زيادة التعرق</p><p dir="RTL">- ألم في العظام والمفاصل (ألم مفصلي)</p><p dir="RTL">إذا تعرضتِ لحدوث أيٍّ من الآثار السابقة فاستشيري الطبيب.</p><p dir="RTL"><strong>بعض الآثار الجانبية الشائعة (</strong>قد تؤثر في مريض واحد من كل 10 مرضى):</p><p dir="RTL">- الطفح الجلدي</p><p dir="RTL">- الصداع</p><p dir="RTL">- الدوار</p><p dir="RTL">- التوعك (الشعور العام بالاعياء)</p><p dir="RTL">- اضطرابات في المعدة والأمعاء مثل الغثيان، القيء، عسر الهضم، الإمساك، الإسهال</p><p dir="RTL">- زيادة أو فقدان الشهية</p><p dir="RTL">- ألم في العضلات</p><p dir="RTL">- انخفاض كثافة العظم ونحافته (هشاشة العظام)، مما يؤدي إلى حدوث كسور في بعض الحالات (انظري &quot;المتابعة خلال فترة العلاج بتريزول&quot; في قسم 3)</p><p dir="RTL">- تورم الذراعين، اليدين، القدمين، الكاحلين (وذمة)</p><p dir="RTL">- الاكتئاب</p><p dir="RTL">&nbsp;- زيادة الوزن</p><p dir="RTL">- تساقط الشعر</p><p dir="RTL">- ارتفاع ضغط الدم</p><p dir="RTL">- ألم في منطقة البطن</p><p dir="RTL">- جفاف البشرة</p><p dir="RTL">- نزيف مهبلي</p><p dir="RTL">- خفقان، سرعة ضربات القلب</p><p dir="RTL">- خشونة المفاصل (التهاب المفاصل)</p><p dir="RTL">- ألم بالصدر</p><p dir="RTL">إذا تعرضت لحدوث أيٍّ من الآثار السابقة فاستشيري الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض الآثار الجانبية الغير شائعة (</strong>قد تؤثر في مريض واحد من 100 مريض):</p><p dir="RTL">- اضطرابات عصبية مثل القلق، التوتر العصبي، حدة الطبع، النعاس، مشكلات في الذاكرة، الرغبة في النوم، الأرق</p><p dir="RTL">- شعور بالألم أو الحرقة في اليدين أو الرسغين (متلازمة النفق الرسغي)</p><p dir="RTL">- فقدان الإحساس، وخاصة حاسة اللمس</p><p dir="RTL">- مشكلات في العين مثل عدم وضوح الرؤية وتهيج العين</p><p dir="RTL">- خفقان، ضربات قلب سريعة</p><p dir="RTL">-اضطرابات في الجلد مثل الحكة (ارتكاريا)</p><p dir="RTL">- زيادة الإفرزات المهبلية أو جفاف المهبل</p><p dir="RTL">- تيبس المفاصل (التهاب المفاصل)</p><p dir="RTL">- ألم في الثدي</p><p dir="RTL">- حمى</p><p dir="RTL">شعور بالعطش، اضطراب حاسة التذوق، جفاف الفم</p><p dir="RTL">- جفاف الأغشية المخاطية</p><p dir="RTL">- زيادة الوزن</p><p dir="RTL">- عدوى الجهاز البولي، زيادة عدد مرات التبول</p><p dir="RTL">- السعال</p><p dir="RTL">- زيادة مستوى الإنزيمات</p><p dir="RTL">- اصفرار الجلد والعينين</p><p dir="RTL">- ارتفاع مستوى البيليروبين في الدم ( مادة تنتج عن تكسير أو تحلل خلايا الدم الحمراء)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية التي لا يُعرف عدد مرات حدوثها (</strong>لا يمكن تحديد معدل تكرارها من البيانات المتاحة<strong>)</strong></p><p dir="RTL">الأصبع الزنادية، وهي حالة يكون فيها أصبع الإبهام أو أي أصبع آخر من أصابع اليد في الوضع المنحني مثل وضع الأصبع على زناد البندقية. إذا تعرضت لحدوث أيٍّ من الآثار السابقة فاستشيري الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت عليك أي آثار جانبية، اخبري الطبيب أو الصيدلي. ويشمل ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</p><p dir="RTL">بإمكانكم المساهمة في تقديم المزيد من المعلومات المتعلقة بسلامة هذا الدواء، و ذلك بالإبلاغ عن ظهور أي آثار جانبية له.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- يحفظ هذا الدواء بعيداً عن متناول الأطفال.</p><p dir="RTL">- لا يستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية الموضح على العلبة بعد كلمة EXP. يشير تاريخ الصلاحية إلى اليوم الأخير من</p><p dir="RTL">الشهر المذكور.</p><p dir="RTL">- يحفظ في درجة حرارة لا تزيد عن 30 ْم.</p><p dir="RTL">- يحفظ في علبته الأصلية لحمايته من الرطوبة.</p><p dir="RTL">- تجنبي استخدام أي عبوة تالفة أو تظهر عليها علامات العبث بها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;<strong>يحتوي </strong><strong>تريزول</strong> <strong>على</strong></p><p dir="RTL">المادة الفعالة وهي ليتروزول. يحتوي كل قرص مغلف على 2,5 ملجم ليتروزول.</p><p dir="RTL">المحتويات الأخرى للقرص من الداخل هي: مونوهيدرات اللاكتوز، وكاربوكسيميثيل الصوديوم النشا، والسليلوز الدقيق البلورات،</p><p dir="RTL">وهايبروميلوز، والسيليكا الغروانية اللا مائية وستيارات الماغنسيوم.</p><p dir="RTL">مكونات الغلاف الخارجي للقرص، أوبادري أصفر، هي: هايبروميلوز، ماكروغول 6000، ثاني أكسيد التيتانيوم (E171)، أكسيد الحديد</p><p dir="RTL">الأصفر (E172)، أكسيد الحديد الأحمر (E172) وتارترازين (E102).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ألشكل الصيدلي لدواء تريزول ومحتويات العبوة</strong></p><p dir="RTL">يتوفر تريزول في شكل أقراص مغلفة صفراء اللون، دائرية، محدبة الوجهين وبدون أي نقوش على كلا الجانبين، ومطبوع على جانب</p><p dir="RTL">واحد الرمز L.</p><p dir="RTL">يتوفر تريزول في عبوة تحتوي على 30 قرصاً (في كل شريط 10 أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مختبرات سينفا، ش.م.</p><p dir="RTL">شارع أولاز شيبي، 10 منطقة بوليغنو الصناعية.</p><p dir="RTL">31620 أوارتي-بامبلونا (نافارا) &ndash; إسبانيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أُجريت آخر مراجعة لهذه النشرة في سبتمبر 2017.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trezol 2.5 mg Film-Coated Tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance: letrozole.
Each film-coated tablet contains 2.5 mg letrozole.
Each tablet contains 45.00 mg of lactose. For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Trezol 2.5 mg are yellow, cylindrical and biconvex film coated tablets.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First-line treatment in postmenopausal women with hormone<strong><em>-</em></strong>dependent advanced breast cancer.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with anti-oestrogens.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.</p><p>Efficacy has not been demonstrated in patients with hormone receptor negative breast cancer.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Adult</em><em> </em><em>and</em><em> </em><em>elderly</em><em> </em><em>patients</em></p><p>The recommended dose of Trezol is 2.5 mg once daily. No dose adjustment is required for elderly patients.</p><p>In patients with advanced or metastatic breast cancer, treatment with letrozole should continue until tumour progression is evident.</p><p>In the adjuvant and extended adjuvant setting, treatment with letrozole should continue for 5 years or until tumour relapse occurs, whichever is first.</p><p>In the adjuvant setting a sequential treatment schedule (letrozole 2 years followed by tamoxifen 3 years) could also be considered (see sections 4.4 and 5.1).</p><p>In the neoadjuvant setting, treatment with letrozole could be continued for 4 to 8 months in order to establish optimal tumour reduction. If the response is not adequate, treatment with letrozole should be discontinued and surgery scheduled and/or further treatment options discussed with the patient.</p><p><em>Paediatric</em><em> </em><em>population</em></p><p>Letrozole is not recommended for use in children and adolescents. The safety and efficacy of letrozole in children and adolescents aged up to 17 years have not been established. Limited data are available and no recommendation on a posology can be made.</p><p><em>Renal</em><em> </em><em>impairment</em></p><p>No dosage adjustment of letrozole is required for patients with renal insufficiency with creatinine clearance &ge;10 ml/min. Insufficient data are available in cases of renal insufficiency with creatinine clearance lower than 10 ml/min (see sections 4.4 and 5.2).</p><p><em>Hepatic</em><em> </em><em>impairment</em></p><p>No dose adjustment of letrozole is required for patients with mild to moderate hepatic insufficiency (Child-Pugh A or B). Insufficient data are available for patients with severe hepatic impairment. Patients with severe hepatic impairment (Child- Pugh C) require close supervision (see sections 4.4 and 5.2).</p><p><u>Method</u><u> </u><u>of</u><u> </u><u>administration</u></p><p>Trezol should be taken orally and can be taken with or without food.</p><p>A missed dose should be taken as soon as the patient remembers. However, if it is almost time for the next dose (within 2 or 3 hours), the missed dose should be skipped, and the patient should go back to her regular dosage schedule.</p><p>Doses should not be doubled because with daily doses over the 2.5 mg recommended dose, over-proportionality in systemic exposure was observed (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
•	Premenopausal endocrine status
•	Pregnancy (see section 4.6)
•	Breast-feeding (see section 4.6)


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Menopausal</u><u> </u><u>status</u></p><p>In patients whose menopausal status is unclear, luteinising hormone (LH), follicle-stimulating hormone (FSH) and/or oestradiol levels should be measured before initiating treatment with letrozole. Only women of postmenopausal endocrine status should receive letrozole.</p><p><u>Renal</u><u> </u><u>impairment</u></p><p>Letrozole has not been investigated in a sufficient number of patients with a creatinine clearance lower than 10 ml/min. The potential risk/benefit to such patients should be carefully considered before administration of letrozole.</p><p><u>Hepatic</u><u> </u><u>impairment</u></p><p>In patients with severe hepatic impairment (Child-Pugh C), systemic exposure and terminal half-life were approximately doubled compared to healthy volunteers. Such patients should therefore be kept under close supervision (see section 5.2).</p><p><u>Bone</u><u> </u><u>effects</u></p><p>Letrozole is a potent oestrogen-lowering agent. Women with a history of osteoporosis and/or fractures, or who are at increased risk of osteoporosis, should have their bone mineral density formally assessed prior to the commencement of adjuvant and extended adjuvant treatment and monitored during and following treatment with letrozole. Treatment or prophylaxis for osteoporosis should be initiated as appropriate and carefully monitored. In the adjuvant setting a sequential treatment schedule (letrozole 2 years followed by tamoxifen 3 years) could also be considered depending on the patient&#39;s safety profile (see sections 4.2, 4.8 and 5.1).</p><p><u>Other</u><u> </u><u>warnings</u></p><p>Co-administration of letrozole with tamoxifen, other anti-oestrogens or oestrogen-containing therapies should be avoided as these substances may diminish the pharmacological action of letrozole (see section 4.5).</p><p>As the tablets contain lactose, Trezol is not recommended for patients with rare hereditary problems of galactose intolerance, of severe lactase deficiency or of glucose-galactose malabsorption.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metabolism of letrozole is partly mediated via CYP2A6 and CYP3A4. Cimetidine, a weak, unspecific inhibitor of CYP450 enzymes, did not affect the plasma concentrations of letrozole. The effect of potent CYP450 inhibitors is unknown.</p><p>There is no clinical experience to date on the use of letrozole in combination with oestrogens or other anticancer agents, other than tamoxifen. Tamoxifen, other anti-oestrogens or oestrogen-containing therapies may diminish the pharmacological action of letrozole. In addition, co-administration of tamoxifen with letrozole has been shown to substantially decrease plasma concentrations of letrozole. Co-administration of letrozole with tamoxifen, other anti- oestrogens or oestrogens should be avoided.</p><p><em>In</em><em> </em><em>vitro,</em><em> </em>letrozole inhibits the cytochrome P450 isoenzymes 2A6 and, moderately, 2C19, but the clinical relevance is unknown. Caution is therefore indicated when giving letrozole concomitantly with medicinal products whose elimination is mainly dependent on these isoenzymes and whose therapeutic index is narrow (e.g. phenytoin, clopidrogel).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of perimenopausal status or child-bearing potential</u></p><p>Letrozole should only be used in women with a clearly established postmenopausal status (see section 4.4). As there are reports of women regaining ovarian function during treatment with letrozole despite a clear postmenopausal status at start of therapy, the physician needs to discuss adequate contraception when necessary.</p><p><u>Pregnancy</u></p><p>Based on human experience in which there have been isolated cases of birth defects (labial fusion, ambiguous genitalia), Letrozole may cause congenital malformations when administered during pregnancy. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Letrozole is contraindicated during pregnancy (see sections 4.3 and 5.3).</p><p><u>Breast-feeding</u></p><p>It is unknown whether letrozole and its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded.</p><p>Letrozole is contraindicated during breast-feeding (see section 4.3).</p><p><u>Fertility</u></p><p>The pharmacological action of letrozole is to reduce oestrogen production by aromatase inhibition. In premenopausal women, the inhibition of oestrogen synthesis leads to feedback increases in gonadotropin (LH, FSH) levels. Increased FSH levels in turn stimulate follicular growth, and can induce ovulation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Letrozole has minor influence on the ability to drive and use machines. Since fatigue and dizziness have been observed with the use of letrozole and somnolence has been reported uncommonly, caution is advised when driving or using machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary</u><u> </u><u>of</u><u> </u><u>the safety profile</u></p><p>The frequencies of adverse reactions for letrozole are mainly based on data collected from clinical trials.</p><p>Up to approximately one third of the patients treated with letrozole in the metastatic setting and approximately 80% of the patients in the adjuvant setting as well as in the extended adjuvant setting experienced adverse reactions. The majority of the adverse reactions occurred during the first few weeks of treatment.</p><p>The most frequently reported adverse reactions in clinical studies were hot flushes, hypercholesterolaemia, arthralgia, fatigue, increased sweating and nausea.</p><p>Important additional adverse reactions that may occur with letrozole are: skeletal events such as osteoporosis and/or bone fractures and cardiovascular events (including cerebrovascular and thromboembolic events). The frequency category for these adverse reactions is described in Table 1.</p><p><u>T</u><u>abu</u><u>lated list of adverse reactions</u></p><p>The frequencies of adverse reactions for letrozole are mainly based on data collected from clinical trials.</p><p>The following adverse drug reactions, listed in Table 1, were reported from clinical studies and from post-marketing experience with letrozole:</p><p>Table 1</p><p>Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:579px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Urinary tract infection</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Tumour pain1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood</strong><strong> </strong><strong>and</strong><strong> </strong><strong>lymphatic</strong><strong> </strong><strong>system</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Leukopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune</strong><strong> </strong><strong>system</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hypercholesterolaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Decreased appetite, increased appetite</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Anxiety (including nervousness), irritability</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache, dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Somnolence, insomnia, memory impairment, dysaesthesia (including paraesthesia, hypoaesthesia), dysgeusia, cerebrovascular accident, carpal tunnel syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cataract, eye irritation, blurred vision</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Palpitations1</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Tachycardia, ischaemic cardiac events (including new or worsening angina, angina requiring surgery, myocardial infarction and myocardial ischaemia)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hot flushes</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Thrombophlebitis (including superficial and deep vein thrombophlebitis)</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Pulmonary embolism, arterial thrombosis, cerebral infarction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory,</strong><strong> </strong><strong>thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dyspnoea, cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal</strong><strong> &nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Nausea, dyspepsia1, constipation, abdominal pain, diarrhoea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dry mouth, stomatitis1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary</strong><strong> &nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Increased hepatic enzymes, hyperbilirubinemia, jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hepatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Alopecia, rash (including erythematous, maculopapular, psoriaform, and vesicular rash), dry skin</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Pruritus, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Angioedema, toxic epidermal necrolysis, erythema multiforme</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal</strong><strong> </strong><strong>and</strong><strong> </strong><strong>connective</strong><strong> </strong><strong>tissue</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Myalgia, bone pain1, osteoporosis, bone fractures, arthritis</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Trigger finger</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal</strong><strong> </strong><strong>and</strong><strong> </strong><strong>urinary</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Pollakiuria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive</strong><strong> </strong><strong>system</strong><strong> </strong><strong>and</strong><strong> </strong><strong>breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Vaginal haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Vaginal discharge, vulvovaginal dryness, breast pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General</strong><strong> </strong><strong>disorders</strong><strong> and</strong><strong> </strong><strong>administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Fatigue (including asthenia, malaise)</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Peripheral oedema, chest pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>General oedema, mucosal dryness, thirst, pyrexia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Weight decreased</p></td></tr></tbody></table><p>1 Adverse drug reactions reported only in the metastatic setting</p><p>Some adverse reactions have been reported with notably different frequencies in the adjuvant treatment setting. The following tables provide information on significant differences in letrozole versus tamoxifen monotherapy and in the letrozole -tamoxifen sequential treatment therapy:</p><p>Table 2 Adjuvant letrozole monotherapy versus tamoxifen monotherapy &ndash; adverse events with significant differences</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:578px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Letrozole,</strong><strong> </strong><strong>incidence rate</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen,</strong><strong> </strong><strong>incidence&nbsp; rate</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>N=2448</strong></p></td><td style="vertical-align:top"><p><strong>N=2447</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>During</strong><strong> </strong><strong>treatment</strong><strong> </strong><strong>(Median</strong><strong> </strong><strong>5y)</strong></p></td><td style="vertical-align:top"><p><strong>Any</strong><strong> </strong><strong>time after randomization (Median 8y)</strong></p></td><td style="vertical-align:top"><p><strong>During</strong><strong> </strong><strong>treatment</strong><strong> </strong><strong>(Median</strong><strong> </strong><strong>5y)</strong></p></td><td style="vertical-align:top"><p><strong>Any</strong><strong> </strong><strong>time after randomization (Median 8y)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bone fracture</p></td><td style="vertical-align:top"><p>10.2%</p></td><td style="vertical-align:top"><p>14.7%</p></td><td style="vertical-align:top"><p>7.2%</p></td><td style="vertical-align:top"><p>11.4%</p></td></tr><tr><td style="vertical-align:top"><p>Osteoporosis</p></td><td style="vertical-align:top"><p>5.1%</p></td><td style="vertical-align:top"><p>5.1%</p></td><td style="vertical-align:top"><p>2.7%</p></td><td style="vertical-align:top"><p>2.7%</p></td></tr><tr><td style="vertical-align:top"><p>Thromboembolic&nbsp; events</p></td><td style="vertical-align:top"><p>2.1%</p></td><td style="vertical-align:top"><p>3.2%</p></td><td style="vertical-align:top"><p>3.6%</p></td><td style="vertical-align:top"><p>4.6%</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>1.0%</p></td><td style="vertical-align:top"><p>1.7%</p></td><td style="vertical-align:top"><p>0.5%</p></td><td style="vertical-align:top"><p>1.1%</p></td></tr><tr><td style="vertical-align:top"><p>Endometrial hyperplasia / endometrial cancer</p></td><td style="vertical-align:top"><p>0.2%</p></td><td style="vertical-align:top"><p>0.4%</p></td><td style="vertical-align:top"><p>2.3%</p></td><td style="vertical-align:top"><p>2.9%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Note: &ldquo;During treatment&rdquo; includes 30 days after last dose. &ldquo;Any time&rdquo; includes follow-up period after completion or discontinuation of study treatment.</p><p>Differences were based on risk ratios and 95% confidence intervals.</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 3 Sequential treatment versus letrozole monotherapy &ndash; adverse events with significant differences</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>letrozole</strong><strong> </strong><strong>monotherapy</strong></p></td><td style="vertical-align:top"><p><strong>letrozole -&gt;tamoxifen</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen-&gt;</strong> <strong>letrozole</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>N=1535</strong></p></td><td style="vertical-align:top"><p><strong>N=1527</strong></p></td><td style="vertical-align:top"><p><strong>N=1541</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>5 years</strong></p></td><td style="vertical-align:top"><p><strong>2 yrs-&gt; 3 yrs</strong></p></td><td style="vertical-align:top"><p><strong>2 yrs-&gt; 3 yrs</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bone fractures</p></td><td style="vertical-align:top"><p>10.0%</p></td><td style="vertical-align:top"><p>7.7%*</p></td><td style="vertical-align:top"><p>9.7%</p></td></tr><tr><td style="vertical-align:top"><p>Endometrial proliferative disorders</p></td><td style="vertical-align:top"><p>0.7%</p></td><td style="vertical-align:top"><p>3.4%**</p></td><td style="vertical-align:top"><p>1.7%**</p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia</p></td><td style="vertical-align:top"><p>52.5%</p></td><td style="vertical-align:top"><p>44.2%*</p></td><td style="vertical-align:top"><p>40.8%*</p></td></tr><tr><td style="vertical-align:top"><p>Hot flushes</p></td><td style="vertical-align:top"><p>37.6%</p></td><td style="vertical-align:top"><p>41.7%**</p></td><td style="vertical-align:top"><p>43.9%**</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal bleeding</p></td><td style="vertical-align:top"><p>6.3%</p></td><td style="vertical-align:top"><p>9.6%**</p></td><td style="vertical-align:top"><p>12.7%**</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=ES style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin;mso-field-lock:yes'></span>SHAPE<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT<span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group
 id="_x0000_s1026" style='width:432.4pt;height:52.6pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="10344,1049" o:allowincell="f">
 <v:shape id="_x0000_s1027" style='position:absolute;left:8;top:1032;width:10327;
  height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10327,20" o:allowincell="f"
  path="m,hhl10326,e" filled="f" strokecolor="#2c2c2c" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1028" style='position:absolute;left:10327;
  top:8;width:20;height:1032;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,1032" o:allowincell="f"
  path="m,hhl,1031e" filled="f" strokecolor="#2c2c2c" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1029" style='position:absolute;left:15;top:8;
  width:20;height:1032;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,1032" o:allowincell="f"
  path="m,hhl,1031e" filled="f" strokecolor="gray" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1030" style='position:absolute;left:23;top:1017;
  width:10297;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10297,20" o:allowincell="f"
  path="m,hhl10296,e" filled="f" strokecolor="gray" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1031" style='position:absolute;left:10312;
  top:8;width:20;height:1017;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,1017" o:allowincell="f"
  path="m,hhl,1016e" filled="f" strokecolor="gray" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1032" style='position:absolute;left:30;top:8;
  width:20;height:1017;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,1017" o:allowincell="f"
  path="m,hhl,1016e" filled="f" strokecolor="#2c2c2c" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
  path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1033" type="#_x0000_t202" style='position:absolute;
  left:23;top:8;width:10297;height:1017;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' o:allowincell="f" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1033' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:2.2pt;margin-bottom:.0001pt;punctuation-wrap:simple;
     mso-line-break-override:restrictions'><span style='mso-ansi-language:EN-US'>*<span
     style='letter-spacing:.95pt'> </span><span style='letter-spacing:-.05pt'>Significantly</span><span
     style='letter-spacing:1.45pt'> </span>less<span style='letter-spacing:
     1.45pt'> </span><span style='letter-spacing:-.05pt'>than</span><span
     style='letter-spacing:.8pt'> </span>with<span style='letter-spacing:.8pt'>
     </span><span style='letter-spacing:-.1pt'>letrozole</span><span
     style='letter-spacing:.75pt'> </span><span style='letter-spacing:-.15pt'>monotherapy</span><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:6.25pt;margin-right:0in;margin-bottom:
     0in;margin-left:2.2pt;margin-bottom:.0001pt;punctuation-wrap:simple;
     mso-line-break-override:restrictions'><span style='letter-spacing:-.05pt;
     mso-ansi-language:EN-US'>**</span><span style='letter-spacing:.95pt;
     mso-ansi-language:EN-US'> </span><span style='letter-spacing:-.05pt;
     mso-ansi-language:EN-US'>Significantly</span><span style='letter-spacing:
     1.5pt;mso-ansi-language:EN-US'> </span><span style='letter-spacing:-.1pt;
     mso-ansi-language:EN-US'>more</span><span style='letter-spacing:.8pt;
     mso-ansi-language:EN-US'> </span><span style='letter-spacing:-.05pt;
     mso-ansi-language:EN-US'>than</span><span style='letter-spacing:.8pt;
     mso-ansi-language:EN-US'> </span><span style='mso-ansi-language:EN-US'>with<span
     style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.1pt'>letrozole</span><span
     style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.15pt'>monotherapy</span><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:6.25pt;margin-right:0in;margin-bottom:
     0in;margin-left:2.2pt;margin-bottom:.0001pt;punctuation-wrap:simple;
     mso-line-break-override:restrictions'><span style='letter-spacing:-.1pt;
     mso-ansi-language:EN-US'>Note</span><span style='letter-spacing:.6pt;
     mso-ansi-language:EN-US'> </span><span style='mso-ansi-language:EN-US'>:<span
     style='letter-spacing:1.1pt'> </span><span style='letter-spacing:-.15pt'>Reporting</span><span
     style='letter-spacing:.6pt'> </span><span style='letter-spacing:-.15pt'>period</span><span
     style='letter-spacing:.65pt'> </span>is<span style='letter-spacing:1.25pt'>
     </span><span style='letter-spacing:-.15pt'>during</span><span
     style='letter-spacing:.6pt'> </span><span style='letter-spacing:-.05pt'>treatment</span><span
     style='letter-spacing:1.1pt'> </span><span style='letter-spacing:-.1pt'>or</span><span
     style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.05pt'>within</span><span
     style='letter-spacing:.6pt'> </span><span style='letter-spacing:-.1pt'>30</span><span
     style='letter-spacing:.65pt'> </span><span style='letter-spacing:-.05pt'>days</span><span
     style='letter-spacing:1.25pt'> </span><span style='letter-spacing:-.1pt'>of</span><span
     style='letter-spacing:.25pt'> </span><span style='letter-spacing:-.05pt'>stopping</span><span
     style='letter-spacing:.6pt'> </span><span style='letter-spacing:-.05pt'>treatment</span><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:anchorlock/>
</v:group><![endif]--><img width="578" height="71" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
lang=ES style='font-size:11.0pt;font-family:"Times New Roman",serif'><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:429.3pt;height:52.45pt'>
 <v:imagedata croptop="-1" cropbottom="1"/>
 <o:lock v:ext="edit" rotation="t" position="t"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><u>Description</u><u> </u><u>of</u><u> </u><u>selected adverse reactions</u></p><p><em>Cardiac</em><em> </em><em>adverse</em><em> </em><em>reactions</em></p><p>In the adjuvant setting, in addition to the data presented in Table 2, the following adverse events were reported for letrozole and tamoxifen, respectively (at median treatment duration of 60 months plus 30 days): angina requiring surgery (1.0% vs. 1.0%); cardiac failure (1.1% vs. 0.6%); hypertension (5.6% vs. 5.7%); cerebrovascular accident/transient ischaemic attack (2.1% vs. 1.9%).</p><p>In the extended adjuvant setting for letrozole (median duration of treatment 5 years) and placebo (median duration of treatment 3 years), respectively: angina requiring surgery (0.8% vs. 0.6%); new or worsening angina (1.4% vs. 1.0%); myocardial infarction (1.0% vs. 0.7%); thromboembolic event* (0.9% vs. 0.3%); stroke/transient ischaemic attack* (1.5% vs. 0.8%) were reported.</p><p>Events marked * were statistically significantly different in the two treatment arms. <em>Skeletal adverse reactions</em></p><p>For skeletal safety data from the adjuvant setting, please refer to Table 2.</p><p>In the extended adjuvant setting, significantly more patients treated with letrozole experienced bone fractures or osteoporosis (bone fractures, 10.4% and osteoporosis, 12.2%) than patients in the placebo arm (5.8% and 6.4%, respectively). Median duration of treatment was 5 years for letrozole, compared with 3 years for placebo.</p><p><u>Reporting</u><u> </u><u>of</u><u> </u><u>suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Isolated cases of overdose with letrozole have been reported.</p><p>No specific treatment for overdose is known; treatment should be symptomatic and supportive.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Endocrine therapy. Hormone antagonist and related agents: aromatase inhibitor, ATC code: L02BG04.</p><p><u>Pharmacodynamic</u><u> </u><u>effects</u></p><p>The elimination of oestrogen-mediated growth stimulation is a prerequisite for tumour response in cases where the growth of tumour tissue depends on the presence of oestrogens and endocrine therapy is used. In postmenopausal women, oestrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens - primarily androstenedione and testosterone - to oestrone and oestradiol. The suppression of oestrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.</p><p>Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the aromatase cytochrome P450, resulting in a reduction of oestrogen biosynthesis in all tissues where present.</p><p>In healthy postmenopausal women, single doses of 0.1 mg, 0.5 mg, and 2.5 mg letrozole suppress serum oestrone and oestradiol by 75%, 78% and 78% from baseline respectively. Maximum suppression is achieved in 48-78 hours.</p><p>In postmenopausal patients with advanced breast cancer, daily doses of 0.1 mg to 5 mg suppressed plasma concentration of oestradiol, oestrone, and oestrone sulphate by 75-95% from baseline in all patients treated. With doses of 0.5 mg and higher, many values of oestrone and oestrone sulphate were below the limit of detection in the assays, indicating that higher oestrogen suppression is achieved with these doses. Oestrogen suppression was maintained throughout treatment in all these patients.</p><p>Letrozole is highly specific in inhibiting aromatase activity. Impairment of adrenal steroidogenesis has not been observed. No clinically relevant changes were found in the plasma concentrations of cortisol, aldosterone, 11- deoxycortisol, 17-hydroxyprogesterone, and ACTH or in plasma renin activity among postmenopausal patients treated with a daily dose of letrozole 0.1 to 5 mg. The ACTH stimulation test performed after 6 and 12 weeks of treatment with daily doses of 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 2.5 mg, and 5 mg did not indicate any attenuation of aldosterone or cortisol production. Thus, glucocorticoid and mineralocorticoid supplementation is not necessary.</p><p>No changes were noted in plasma concentrations of androgens (androstenedione and testosterone) among healthy postmenopausal women after 0.1 mg, 0.5 mg, and 2.5 mg single doses of letrozole or in plasma concentrations of androstenedione among postmenopausal patients treated with daily doses of 0.1 mg to 5 mg, indicating that the blockade of oestrogen biosynthesis does not lead to accumulation of androgenic precursors. Plasma levels of LH and FSH are not affected by letrozole in patients, nor is thyroid function as evaluated by TSH, T4, and T3 uptake test.</p><p><u>Adjuvant</u><u> </u><u>treatment</u> <em>&nbsp;</em></p><p><em><u>Study BIG 1-98</u></em></p><p>BIG 1-98 was a multicentre, double-blind study in which over 8,000 postmenopausal women with hormone receptor- positive early breast cancer were randomised to one of the following treatments: A. tamoxifen for 5 years; B. letrozole for 5 years; C. tamoxifen for 2 years followed by letrozole for 3 years; D. letrozole for 2 years followed by tamoxifen for 3 years.</p><p>The primary endpoint was disease-free survival (DFS); secondary efficacy endpoints were time to distant metastasis (TDM), distant disease-free survival (DDFS), overall survival (OS), systemic disease-free survival (SDFS), invasive contralateral breast cancer and time to breast cancer recurrence.</p><p><em>Efficacy</em><em> </em><em>results at a median follow-up of 26 and 60 months</em></p><p>Data in Table 4 reflect the results of the Primary Core Analysis (PCA) based on data from the monotherapy arms (A and</p><p>B) and from the two switching arms (C and D) at a median treatment duration of 24 months and a median follow-up of 26 months and at a median treatment duration of 32 months and a median follow-up of 60 months.</p><p>The 5-year DFS rates were 84% for letrozole and 81.4% for tamoxifen.</p><p>Table 4 Primary Core Analysis: Disease-free and overall survival, at a median follow-up of 26 months and at median follow-up of 60 months (ITT population)</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:597px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p><strong>Primary</strong><strong> </strong><strong>Core</strong><strong> </strong><strong>Analysis</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Median</strong><strong> </strong><strong>follow-up 26 months</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Median</strong><strong> </strong><strong>follow-up 60 months</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>letrozole</strong><strong> </strong><strong>N=4003</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong><strong> </strong><strong>N=4007</strong></p></td><td style="vertical-align:top"><p><strong>HR1</strong><strong>&nbsp;</strong><strong>(95% </strong><strong>CI)</strong><strong> </strong><strong><em>P</em></strong></p></td><td style="vertical-align:top"><p><strong>letrozole</strong><strong> </strong><strong>N=4003</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong><strong> </strong><strong>N=4007</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HR1</strong><strong>&nbsp;</strong><strong>(95% </strong><strong>CI)</strong><strong> </strong><strong><em>P</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Disease-free survival (primary) -</p></td><td rowspan="3" style="vertical-align:top"><p>351</p></td><td rowspan="3" style="vertical-align:top"><p>428</p></td><td style="vertical-align:top"><p>0.81</p></td><td rowspan="3" style="vertical-align:top"><p>585</p></td><td rowspan="3" style="vertical-align:top"><p>664</p></td><td colspan="2" style="vertical-align:top"><p>0.86</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>events (protocol definition2)</p></td><td style="vertical-align:top"><p>(0.70, 0.93)</p></td><td colspan="2" style="vertical-align:top"><p>(0.77, 0.96)</p></td></tr><tr><td style="vertical-align:top"><p>0.003</p></td><td colspan="2" style="vertical-align:top"><p>0.008</p></td></tr><tr><td style="vertical-align:top"><p>Overall survival (secondary)</p></td><td rowspan="2" style="vertical-align:top"><p>166</p></td><td rowspan="2" style="vertical-align:top"><p>192</p></td><td style="vertical-align:top"><p>0.86</p></td><td rowspan="2" style="vertical-align:top"><p>330</p></td><td rowspan="2" style="vertical-align:top"><p>374</p></td><td colspan="2" style="vertical-align:top"><p>0.87</p></td></tr><tr><td style="vertical-align:top"><p>Number of deaths</p></td><td style="vertical-align:top"><p>(0.70, 1.06)</p></td><td colspan="2" style="vertical-align:top"><p>(0.75, 1.01)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>HR = Hazard ratio; CI = Confidence interval</p><p>1&nbsp;&nbsp; Log rank test, stratified by randomisation option and use of chemotherapy (yes/no)</p><p>2&nbsp;&nbsp; DFS events: loco-regional recurrence, distant metastasis, invasive contralateral breast cancer, second (non-breast) primary malignancy, death from any cause without a prior cancer event.</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Results</em><em> </em><em>at</em><em> </em><em>a median follow-up of 96 months (monotherapy arms only)</em></p><p>The Monotherapy Arms Analysis (MAA) long-term update of the efficacy of letrozole monotherapy compared to tamoxifen monotherapy (median duration of adjuvant treatment: 5 years) is presented in Table 5.</p><p>Table 5 Monotherapy Arms Analysis: Disease-free and overall survival at a median follow-up of 96 months (ITT population)</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>letrozole</strong><strong> </strong><strong>N=2463</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong><strong> </strong><strong>N=2459</strong></p></td><td style="vertical-align:top"><p><strong>Hazard</strong><strong> </strong><strong>Ratio1 (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong><em>P </em></strong><strong>Value</strong></p></td></tr><tr><td style="vertical-align:top"><p>Disease-free survival events (primary) 2</p></td><td style="vertical-align:top"><p>626</p></td><td style="vertical-align:top"><p>698</p></td><td style="vertical-align:top"><p>0.87 (0.78, 0.97)</p></td><td style="vertical-align:top"><p>0.01</p></td></tr><tr><td style="vertical-align:top"><p>Time to distant metastasis (secondary)</p></td><td style="vertical-align:top"><p>301</p></td><td style="vertical-align:top"><p>342</p></td><td style="vertical-align:top"><p>0.86 (0.74, 1.01)</p></td><td style="vertical-align:top"><p>0.06</p></td></tr><tr><td style="vertical-align:top"><p>Overall survival (secondary) - deaths</p></td><td style="vertical-align:top"><p>393</p></td><td style="vertical-align:top"><p>436</p></td><td style="vertical-align:top"><p>0.89 (0.77, 1.02)</p></td><td style="vertical-align:top"><p>0.08</p></td></tr><tr><td style="vertical-align:top"><p>Censored analysis of DFS3</p></td><td style="vertical-align:top"><p>626</p></td><td style="vertical-align:top"><p>649</p></td><td style="vertical-align:top"><p>0.83 (0.74, 0.92)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Censored analysis of OS3</p></td><td style="vertical-align:top"><p>393</p></td><td style="vertical-align:top"><p>419</p></td><td style="vertical-align:top"><p>0.81 (0.70, 0.93)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>1 Log rank test, stratified by randomisation option and use of chemotherapy (yes/no)</p></td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=ES style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin;mso-field-lock:yes'></span>SHAPE<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT<span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group
 id="_x0000_s1026" style='width:460.1pt;height:51.7pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="10344,1093" o:allowincell="f">
 <v:shape id="_x0000_s1027" style='position:absolute;left:8;top:1077;width:10327;
  height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10327,20" o:allowincell="f"
  path="m,hhl10326,e" filled="f" strokecolor="#2c2c2c" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1028" style='position:absolute;left:10327;
  top:8;width:20;height:1076;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,1076" o:allowincell="f"
  path="m,hhl,1076e" filled="f" strokecolor="#2c2c2c" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1029" style='position:absolute;left:15;top:8;
  width:20;height:1076;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,1076" o:allowincell="f"
  path="m,hhl,1076e" filled="f" strokecolor="gray" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1030" style='position:absolute;left:23;top:1062;
  width:10297;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10297,20" o:allowincell="f"
  path="m,hhl10296,e" filled="f" strokecolor="gray" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1031" style='position:absolute;left:10312;
  top:8;width:20;height:1062;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,1062" o:allowincell="f"
  path="m,hhl,1061e" filled="f" strokecolor="gray" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1032" style='position:absolute;left:30;top:8;
  width:20;height:1062;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,1062" o:allowincell="f"
  path="m,hhl,1061e" filled="f" strokecolor="#2c2c2c" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
  path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1033" type="#_x0000_t202" style='position:absolute;
  left:23;top:8;width:10297;height:1062;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' o:allowincell="f" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1033' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:3.95pt;margin-right:11.35pt;
     margin-bottom:0in;margin-left:2.2pt;margin-bottom:.0001pt;text-indent:
     0in;line-height:102%;mso-list:l4 level1 lfo6;tab-stops:9.75pt;punctuation-wrap:
     simple;mso-line-break-override:restrictions'><![if !supportLists]><span
     style='font-size:8.0pt;line-height:102%;mso-fareast-font-family:Arial;
     position:relative;top:-3.5pt;mso-text-raise:3.5pt;mso-font-width:101%;
     mso-ansi-language:EN-US'><span style='mso-list:Ignore'>2<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span style='letter-spacing:-.1pt;mso-ansi-language:EN-US'>DFS</span><span
     style='letter-spacing:1.4pt;mso-ansi-language:EN-US'> </span><span
     style='letter-spacing:-.2pt;mso-ansi-language:EN-US'>events:</span><span
     style='letter-spacing:1.55pt;mso-ansi-language:EN-US'> </span><span
     style='letter-spacing:-.15pt;mso-ansi-language:EN-US'>loco-regional</span><span
     style='letter-spacing:1.25pt;mso-ansi-language:EN-US'> </span><span
     style='letter-spacing:-.1pt;mso-ansi-language:EN-US'>recurrence,</span><span
     style='letter-spacing:1.5pt;mso-ansi-language:EN-US'> </span><span
     style='mso-ansi-language:EN-US'>distant<span style='letter-spacing:1.5pt'>
     </span><span style='letter-spacing:.05pt'>metastasis,</span><span
     style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.3pt'>invasive</span><span
     style='letter-spacing:.95pt'> </span><span style='letter-spacing:-.1pt'>contralateral</span><span
     style='letter-spacing:1.25pt'> </span><span style='letter-spacing:-.1pt'>breast</span><span
     style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.1pt'>cancer,</span><span
     style='letter-spacing:1.55pt'> </span>second<span style='letter-spacing:
     .9pt'> </span><span style='letter-spacing:-.15pt'>(non-breast)</span><span
     style='letter-spacing:4.4pt;mso-font-width:102%'> </span><span
     style='letter-spacing:-.15pt'>primary</span><span style='letter-spacing:
     1.3pt'> </span><span style='letter-spacing:-.1pt'>malignancy,</span><span
     style='letter-spacing:1.25pt'> </span><span style='letter-spacing:-.1pt'>death</span><span
     style='letter-spacing:.65pt'> </span><span style='letter-spacing:-.25pt'>from</span><span
     style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.15pt'>any</span><span
     style='letter-spacing:1.35pt'> </span>cause<span style='letter-spacing:
     .65pt'> </span><span style='letter-spacing:-.1pt'>without</span><span
     style='letter-spacing:1.25pt'> </span>a<span style='letter-spacing:.65pt'>
     </span><span style='letter-spacing:-.15pt'>prior</span><span
     style='letter-spacing:.65pt'> </span>cancer<span style='letter-spacing:
     .6pt'> </span><span style='letter-spacing:-.25pt'>event.</span><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:6.15pt;margin-right:0in;margin-bottom:
     0in;margin-left:8.95pt;margin-bottom:.0001pt;text-indent:-6.75pt;
     mso-list:l4 level1 lfo6;tab-stops:9.0pt;punctuation-wrap:simple;
     mso-line-break-override:restrictions'><![if !supportLists]><span
     style='font-size:8.0pt;mso-fareast-font-family:Arial;position:relative;
     top:-3.5pt;mso-text-raise:3.5pt;mso-font-width:101%;mso-ansi-language:
     EN-US'><span style='mso-list:Ignore'>3<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='letter-spacing:-.2pt;mso-ansi-language:EN-US'>Observations</span><span
     style='letter-spacing:1.3pt;mso-ansi-language:EN-US'> </span><span
     style='mso-ansi-language:EN-US'>in<span style='letter-spacing:.7pt'> </span>the<span
     style='letter-spacing:.7pt'> </span><span style='letter-spacing:-.05pt'>tamoxifen</span><span
     style='letter-spacing:.7pt'> </span><span style='letter-spacing:-.15pt'>arm</span><span
     style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>censored</span><span
     style='letter-spacing:.7pt'> </span><span style='letter-spacing:-.1pt'>at</span><span
     style='letter-spacing:1.2pt'> </span>the<span style='letter-spacing:.7pt'>
     </span><span style='letter-spacing:-.05pt'>date</span><span
     style='letter-spacing:.7pt'> </span><span style='letter-spacing:-.1pt'>of</span><span
     style='letter-spacing:.35pt'> </span><span style='letter-spacing:.3pt'>s</span><span
     style='letter-spacing:-.2pt'>e</span>l<span style='letter-spacing:-.2pt'>e</span><span
     style='letter-spacing:.3pt'>c</span><span style='letter-spacing:.2pt'>t</span>i<span
     style='letter-spacing:-1.15pt'>v</span><span style='letter-spacing:-.2pt'>e</span>ly<span
     style='letter-spacing:1.35pt'> </span>switching<span style='letter-spacing:
     .7pt'> </span><span style='letter-spacing:.05pt'>to</span><span
     style='letter-spacing:.65pt'> </span><span style='letter-spacing:-.05pt'>letrozole</span><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="614" height="70" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
lang=ES style='font-size:11.0pt;font-family:"Times New Roman",serif'><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:460.1pt;height:51.7pt'>
 <v:imagedata croptop="-1" cropbottom="1"/>
 <o:lock v:ext="edit" rotation="t" position="t"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><em>Sequential</em><em> </em><em>Treatments</em><em> </em><em>Analysis</em><em> </em><em>(STA)</em></p><p>The Sequential Treatments Analysis (STA) addresses the second primary question of BIG 1-98, namely whether sequencing of tamoxifen and letrozole would be superior to monotherapy. There were no significant differences in DFS, OS, SDFS, or DDFS from switch with respect to monotherapy (Table 6).</p><p>Table 6 Sequential treatments analysis of disease-free survival with letrozole as initial endocrine agent (STA switch population)</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Number of events1</strong></p></td><td style="vertical-align:top"><p><strong>Hazard</strong><strong> </strong><strong>ratio2</strong></p></td><td style="vertical-align:top"><p><strong>(97.5%</strong><strong> </strong><strong>confidence interval)</strong></p></td><td style="vertical-align:top"><p><strong>Cox</strong><strong> </strong><strong>model</strong><strong> </strong><strong><em>P</em></strong><strong>-</strong><strong> </strong><strong>value</strong></p></td></tr><tr><td style="vertical-align:top"><p>[Letrozole&rarr;]Tamoxifen</p></td><td style="vertical-align:top"><p><strong>1460</strong></p></td><td style="vertical-align:top"><p><strong>254</strong></p></td><td style="vertical-align:top"><p><strong>1.03</strong></p></td><td style="vertical-align:top"><p><strong>(0.84,</strong><strong> </strong><strong>1.26)</strong></p></td><td style="vertical-align:top"><p><strong>0.72</strong></p></td></tr><tr><td style="vertical-align:top"><p>Letrozole</p></td><td style="vertical-align:top"><p><strong>1464</strong></p></td><td style="vertical-align:top"><p><strong>249</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>1&nbsp;&nbsp; Protocol definition, including second non-breast primary malignancies, after switch / beyond two years</p><p>2&nbsp;&nbsp; Adjusted by chemotherapy use</p></td></tr></tbody></table><p>There were no significant differences in DFS, OS, SDFS or DDFS in any of the STA from randomisation pairwise comparisons (Table 7).</p><p>Table 7 Sequential Treatments Analyses from randomisation (STA-R) of disease-free survival (ITT STA-R population)</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole&rarr;Tamoxifen</strong></p></td><td style="vertical-align:top"><p><strong>Letrozole</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>1540</p></td><td style="vertical-align:top"><p>1546</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with DFS events (protocol definition)</p></td><td style="vertical-align:top"><p>330</p></td><td style="vertical-align:top"><p>319</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio1&nbsp;(99% CI)</p></td><td colspan="2" style="vertical-align:top"><p>1.04 (0.85, 1.27)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole&rarr;Tamoxifen</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen2</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>1540</p></td><td style="vertical-align:top"><p>1548</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with DFS events (protocol definition)</p></td><td style="vertical-align:top"><p>330</p></td><td style="vertical-align:top"><p>353</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio1&nbsp;(99% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.92 (0.75, 1.12)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1&nbsp;&nbsp; Adjusted by chemotherapy use (yes/no)</p><p>2&nbsp;&nbsp; 626 (40%) patients selectively crossed to letrozole after tamoxifen arm unblinded in 2005</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em><u>Study D2407</u></em></p><p>Study D2407 is an open-label, randomised, multicentre post approval safety study designed to compare the effects of adjuvant treatment with letrozole and tamoxifen on bone mineral density (BMD) and serum lipid profiles. A total of 262 patients were assigned either letrozole for 5 years or tamoxifen for 2 years followed by letrozole for 3 years.</p><p>At 24 months there was a statistically significant difference in the primary end-point; the lumbar spine BMD (L2-L4) showed a median decrease of 4.1% for letrozole compared to a median increase of 0.3% for tamoxifen.</p><p>No patient with a normal BMD at baseline became osteoporotic during 2 years of treatment and only 1 patient with osteopenia at baseline (T score of -1.9) developed osteoporosis during the treatment period (assessment by central review).</p><p>The results for total hip BMD were similar to those for lumbar spine but less pronounced.</p><p>There was no significant difference between treatments in the rate of fractures &ndash; 15% in the letrozole arm, 17% in the tamoxifen arm.</p><p>Median total cholesterol levels in the tamoxifen arm were decreased by 16% after 6 months compared to baseline and this decrease was maintained at subsequent visits up to 24 months. In the letrozole arm, total cholesterol levels were relatively stable over time, giving a statistically significant difference in favour of tamoxifen at each time point.</p><p><em><u>Extended</u></em><em><u> </u></em><em><u>adjuvant</u></em><em><u> </u></em><em><u>treatment</u></em><em><u> </u></em><em><u>(MA-17)</u></em></p><p>In a multicentre, double-blind, randomised, placebo-controlled study (MA-17), over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who had completed adjuvant treatment with tamoxifen (4.5 to 6 years) were randomised to either letrozole or placebo for 5 years.</p><p>The primary endpoint was disease-free survival, defined as the interval between randomisation and the earliest occurrence of loco-regional recurrence, distant metastasis, or contralateral breast cancer.</p><p>The first planned interim analysis at a median follow-up of around 28 months (25% of patients being followed up for at least 38 months), showed that letrozole significantly reduced the risk of breast cancer recurrence by 42% compared with placebo (HR 0.58; 95% CI 0.45, 0.76; <em>P</em>=0.00003). The benefit in favour of letrozole was observed regardless of nodal status. There was no significant difference in overall survival: (letrozole 51 deaths; placebo 62; HR 0.82; 95% CI 0.56, 1.19).</p><p>Consequently, after the first interim analysis the study was unblinded and continued in an open-label fashion and patients in the placebo arm were allowed to switch to letrozole for up to 5 years. Over 60% of eligible patients (disease- free at unblinding) opted to switch to letrozole. The final analysis included 1,551 women who switched from placebo to letrozole at a median of 31 months (range 12 to 106 months) after completion of tamoxifen adjuvant therapy. Median duration for letrozole after switch was 40 months.</p><p>The final analysis conducted at a median follow-up of 62 months confirmed the significant reduction in the risk of breast cancer recurrence with letrozole.</p><p>Table 8 Disease-free and overall survival (Modified ITT population)</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Median follow-up 28 months1</p></td><td colspan="3" style="vertical-align:top"><p>Median follow-up 62 months</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Letrozole N=2582</p></td><td style="vertical-align:top"><p>Placebo N=2586</p></td><td style="vertical-align:top"><p>HR (95% CI)2</p><p><em>P </em>value</p></td><td style="vertical-align:top"><p>Letrozole N=2582</p></td><td style="vertical-align:top"><p>Placebo N=2586</p></td><td style="vertical-align:top"><p>HR (95% CI)2</p><p><em>P </em>value</p></td></tr><tr><td style="vertical-align:top"><p><strong>Disease-free</strong><strong> &nbsp;survival3</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Events</p></td><td rowspan="3" style="vertical-align:top"><p>92 (3.6%)</p></td><td rowspan="3" style="vertical-align:top"><p>155 (6.0%)</p></td><td style="vertical-align:top"><p>0.58</p></td><td rowspan="3" style="vertical-align:top"><p>209 (8.1%)</p></td><td rowspan="3" style="vertical-align:top"><p>286 (11.1%)</p></td><td style="vertical-align:top"><p>0.75</p></td></tr><tr><td style="vertical-align:top"><p>(0.45, 0.76)</p></td><td rowspan="2" style="vertical-align:top"><p>(0.63, 0.89)</p></td></tr><tr><td style="vertical-align:top"><p>0.00003</p></td></tr><tr><td style="vertical-align:top"><p>4-year DFS rate</p></td><td style="vertical-align:top"><p>94.4%</p></td><td style="vertical-align:top"><p>89.8%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>94.4%</p></td><td style="vertical-align:top"><p>91.4%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Disease-free</strong><strong> </strong><strong>survival3,</strong><strong> </strong><strong>including deaths from any cause</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Events</p></td><td rowspan="2" style="vertical-align:top"><p>122 (4.7%)</p></td><td rowspan="2" style="vertical-align:top"><p>193 (7.5%)</p></td><td style="vertical-align:top"><p>0.62</p></td><td style="vertical-align:top"><p>344</p></td><td rowspan="2" style="vertical-align:top"><p>402 (15.5%)</p></td><td style="vertical-align:top"><p>0.89</p></td></tr><tr><td style="vertical-align:top"><p>(0.49, 0.78)</p></td><td style="vertical-align:top"><p>(13.3%)</p></td><td style="vertical-align:top"><p>(0.77, 1.03)</p></td></tr><tr><td style="vertical-align:top"><p>5 year DFS rate</p></td><td style="vertical-align:top"><p>90.5%</p></td><td style="vertical-align:top"><p>80.8%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>88.8%</p></td><td style="vertical-align:top"><p>86.7%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Distant&nbsp; metastases</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Events</p></td><td rowspan="2" style="vertical-align:top"><p>57 (2.2%)</p></td><td rowspan="2" style="vertical-align:top"><p>93 (3.6%)</p></td><td style="vertical-align:top"><p>0.61</p></td><td style="vertical-align:top"><p>142</p></td><td style="vertical-align:top"><p>169</p></td><td style="vertical-align:top"><p>0.88</p></td></tr><tr><td style="vertical-align:top"><p>(0.44, 0.84)</p></td><td style="vertical-align:top"><p>(5.5%)</p></td><td style="vertical-align:top"><p>(6.5%)</p></td><td style="vertical-align:top"><p>(0.70, 1.10)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall</strong><strong> </strong><strong>survival</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Deaths</p></td><td rowspan="2" style="vertical-align:top"><p>51 (2.0%)</p></td><td rowspan="2" style="vertical-align:top"><p>62 (2.4%)</p></td><td style="vertical-align:top"><p>0.82</p></td><td rowspan="2" style="vertical-align:top"><p>236 (9.1%)</p></td><td rowspan="2" style="vertical-align:top"><p>232 (9.0%)</p></td><td style="vertical-align:top"><p>1.13</p></td></tr><tr><td style="vertical-align:top"><p>(0.56, 1.19)</p></td><td style="vertical-align:top"><p>(0.95, 1.36)</p></td></tr><tr><td style="vertical-align:top"><p>Deaths4</p></td><td style="vertical-align:top"><p>- -</p></td><td style="vertical-align:top"><p>- -</p></td><td style="vertical-align:top"><p>- -</p></td><td style="vertical-align:top"><p>2365&nbsp;(9.1%)</p></td><td style="vertical-align:top"><p>1706&nbsp;(6.6%)</p></td><td style="vertical-align:top"><p>0.78</p><p>(0.64, 0.96)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>HR = Hazard ratio; CI = Confidence Interval</p><p>1&nbsp;&nbsp; When the study was unblinded in 2003, 1551 patients in the randomised placebo arm (60% of those eligible to switch &ndash; i.e. who were disease-free) switched to letrozole at a median 31 months after randomisation. The analyses presented here ignore the selective crossover.</p><p>2&nbsp;&nbsp; Stratified by receptor status, nodal status and prior adjuvant chemotherapy.</p><p>3&nbsp;&nbsp; Protocol definition of disease-free survival events: loco-regional recurrence, distant metastasis or contralateral breast cancer.</p><p>4&nbsp;&nbsp; Exploratory analysis, censoring follow-up times at the date of switch (if it occurred) in the placebo arm.</p></td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=ES style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin;mso-field-lock:yes'></span>SHAPE<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT<span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group
 id="_x0000_s1034" style='width:454.6pt;height:41.1pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="10344,854" o:allowincell="f">
 <v:shape id="_x0000_s1035" style='position:absolute;left:8;top:837;width:10327;
  height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10327,20" o:allowincell="f"
  path="m,hhl10326,e" filled="f" strokecolor="#2c2c2c" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1036" style='position:absolute;left:10327;
  top:8;width:20;height:837;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,837" o:allowincell="f"
  path="m,hhl,836e" filled="f" strokecolor="#2c2c2c" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1037" style='position:absolute;left:15;top:8;
  width:20;height:837;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,837" o:allowincell="f"
  path="m,hhl,836e" filled="f" strokecolor="gray" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1038" style='position:absolute;left:23;top:822;
  width:10297;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10297,20" o:allowincell="f"
  path="m,hhl10296,e" filled="f" strokecolor="gray" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1039" style='position:absolute;left:10312;
  top:8;width:20;height:822;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,822" o:allowincell="f"
  path="m,hhl,821e" filled="f" strokecolor="gray" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1040" style='position:absolute;left:30;top:8;
  width:20;height:822;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,822" o:allowincell="f"
  path="m,hhl,821e" filled="f" strokecolor="#2c2c2c" strokeweight=".29886mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1041" type="#_x0000_t202" style='position:absolute;
  left:23;top:8;width:10297;height:822;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' o:allowincell="f" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1041' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:3.2pt;margin-right:0in;margin-bottom:
     0in;margin-left:9.7pt;margin-bottom:.0001pt;text-indent:-7.5pt;mso-list:
     l8 level1 lfo2;tab-stops:9.75pt;punctuation-wrap:simple;mso-line-break-override:
     restrictions'><![if !supportLists]><span lang=ES style='font-size:8.0pt;
     mso-fareast-font-family:Arial;position:relative;top:-3.5pt;mso-text-raise:
     3.5pt;mso-font-width:101%'><span style='mso-list:Ignore'>5<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=ES style='letter-spacing:-.1pt'>Median</span><span
     lang=ES style='letter-spacing:.9pt'> </span><span lang=ES
     style='letter-spacing:-.2pt'>follow-up</span><span lang=ES
     style='letter-spacing:.9pt'> </span><span lang=ES style='letter-spacing:
     -.1pt'>62</span><span lang=ES style='letter-spacing:.9pt'> </span><span
     lang=ES>months.<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:6.4pt;margin-right:0in;margin-bottom:
     0in;margin-left:9.7pt;margin-bottom:.0001pt;text-indent:-7.5pt;mso-list:
     l8 level1 lfo2;tab-stops:9.75pt;punctuation-wrap:simple;mso-line-break-override:
     restrictions'><![if !supportLists]><span style='font-size:8.0pt;
     mso-fareast-font-family:Arial;position:relative;top:-3.5pt;mso-text-raise:
     3.5pt;mso-font-width:101%;mso-ansi-language:EN-US'><span style='mso-list:
     Ignore'>6<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span style='letter-spacing:-.1pt;mso-ansi-language:EN-US'>Median</span><span
     style='letter-spacing:.7pt;mso-ansi-language:EN-US'> </span><span
     style='letter-spacing:-.2pt;mso-ansi-language:EN-US'>follow-up</span><span
     style='letter-spacing:.7pt;mso-ansi-language:EN-US'> </span><span
     style='letter-spacing:-.05pt;mso-ansi-language:EN-US'>until</span><span
     style='letter-spacing:1.0pt;mso-ansi-language:EN-US'> </span><span
     style='letter-spacing:.05pt;mso-ansi-language:EN-US'>switch</span><span
     style='letter-spacing:.7pt;mso-ansi-language:EN-US'> </span><span
     style='letter-spacing:-.1pt;mso-ansi-language:EN-US'>(if</span><span
     style='letter-spacing:.35pt;mso-ansi-language:EN-US'> </span><span
     style='mso-ansi-language:EN-US'>it<span style='letter-spacing:1.25pt'> </span><span
     style='letter-spacing:-.1pt'>occurred)</span><span style='letter-spacing:
     .6pt'> </span><span style='letter-spacing:-.1pt'>37</span><span
     style='letter-spacing:.75pt'> </span>months.<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:anchorlock/>
</v:group><![endif]--><img width="607" height="56" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><span
lang=ES style='font-size:11.0pt;font-family:"Times New Roman",serif'><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:449.95pt;height:41pt'>
 <v:imagedata croptop="-1" cropbottom="1"/>
 <o:lock v:ext="edit" rotation="t" position="t"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>In the MA-17 bone substudy in which concomitant calcium and vitamin D were given, greater decreases in BMD compared to baseline occurred with letrozole compared with placebo. The only statistically significant difference occurred at 2 years and was in total hip BMD (letrozole median decrease of 3.8% vs placebo median decrease of 2.0%).</p><p>In the MA-17 lipid substudy there were no significant differences between letrozole and placebo in total cholesterol or in any lipid fraction.</p><p>In the updated quality of life substudy there were no significant differences between treatments in physical component summary score or mental component summary score, or in any domain score in the SF-36 scale. In the MENQOL scale, significantly more women in the letrozole arm than in the placebo arm were most bothered (generally in the first year of treatment) by those symptoms deriving from oestrogen deprivation &ndash; hot flushes and vaginal dryness. The symptom that bothered most patients in both treatment arms was aching muscles, with a statistically significant difference in favour of placebo.</p><p><em><u>Neoadjuvant</u></em><em><u> </u></em><em><u>treatment</u></em></p><p>A double blind trial (P024) was conducted in 337 postmenopausal breast cancer patients randomly allocated either letrozole 2.5 mg for 4 months or tamoxifen for 4 months. At baseline all patients had tumours stage T2-T4c, N0-2, M0, ER and/or PgR positive and none of the patients would have qualified for breast-conserving surgery. Based on clinical assessment there were 55% objective responses in the letrozole arm versus 36% for the tamoxifen arm (<em>P</em>&lt;0.001). This finding was consistently confirmed by ultrasound (letrozole 35% vs tamoxifen 25%, <em>P</em>=0.04) and mammography (letrozole 34% vs tamoxifen 16%, <em>P</em>&lt;0.001). In total 45% of patients in the letrozole group versus 35% of patients in the tamoxifen group (<em>P</em>=0.02) underwent breast-conserving therapy). During the 4-month pre-operative treatment period, 12% of patients treated with letrozole and 17% of patients treated with tamoxifen had disease progression on clinical assessment.</p><p><u>First-line treatment</u></p><p>One controlled double-blind trial was conducted comparing letrozole 2.5 mg to tamoxifen 20 mg as first-line therapy in postmenopausal women with advanced breast cancer. In 907 women, letrozole was superior to tamoxifen in time to progression (primary endpoint) and in overall objective response, time to treatment failure and clinical benefit.</p><p>The results are summarised in Table 9:</p><p>Table 9 Results at a median follow-up of 32 months</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td style="vertical-align:top"><p><strong>Variable</strong></p></td><td style="vertical-align:top"><p><strong>S</strong><strong>t</strong><strong>a</strong><strong>t</strong><strong>i</strong><strong>s</strong><strong>t</strong><strong>i</strong><strong>c</strong></p></td><td style="vertical-align:top"><p><strong>letrozole</strong></p><p><strong>N=453</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong></p><p><strong>N=454</strong></p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Time</strong><strong> </strong><strong>to</strong><strong> </strong><strong>progression</strong></p></td><td style="vertical-align:top"><p>Median</p></td><td style="vertical-align:top"><p>9.4 months</p></td><td style="vertical-align:top"><p>6.0 months</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI for median)</p></td><td style="vertical-align:top"><p>(8.9, 11.6 months)</p></td><td style="vertical-align:top"><p>(5.4, 6.3 months)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (HR)</p></td><td colspan="2" style="vertical-align:top"><p>0.72</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI for HR)</p></td><td colspan="2" style="vertical-align:top"><p>(0.62, 0.83)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>P</em>&lt;0.0001</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Objective response rate (ORR)</strong></p></td><td style="vertical-align:top"><p>CR+PR</p></td><td style="vertical-align:top"><p>145 (32%)</p></td><td style="vertical-align:top"><p>95 (21%)</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI for rate)</p></td><td style="vertical-align:top"><p>(28, 36%)</p></td><td style="vertical-align:top"><p>(17, 25%)</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio</p></td><td colspan="2" style="vertical-align:top"><p>1.78</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI for odds ratio)</p></td><td colspan="2" style="vertical-align:top"><p>(1.32, 2.40)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>P</em>=0.0002</p></td></tr></tbody></table><p>Time to progression was significantly longer, and response rate significantly higher for letrozole irrespective of whether adjuvant anti-oestrogen therapy had been given or not. Time to progression was significantly longer for letrozole irrespective of dominant site of disease. Median time to progression was 12.1 months for letrozole and 6.4 months for tamoxifen in patients with soft tissue disease only and median 8.3 months for letrozole and 4.6 months for tamoxifen in patients with visceral metastases.</p><p>Study design allowed patients to cross over upon progression to the other therapy or discontinue from the study. Approximately 50% of patients crossed over to the opposite treatment arm and crossover was virtually completed by 36 months. The median time to crossover was 17 months (letrozole to tamoxifen) and 13 months (tamoxifen to letrozole).</p><p>Letrozole treatment in the first-line therapy of advanced breast cancer resulted in a median overall survival of 34 months compared with 30 months for tamoxifen (logrank test P=0.53, not significant). The absence of an advantage for letrozole on overall survival could be explained by the crossover design of the study.</p><p><u>Second-line</u><u> </u><u>treatment</u></p><p>Two well-controlled clinical trials were conducted comparing two letrozole doses (0.5 mg and 2.5 mg) to megestrol acetate and to aminoglutethimide, respectively, in postmenopausal women with advanced breast cancer previously treated with anti-oestrogens.</p><p>Time to progression was not significantly different between letrozole 2.5 mg and megestrol acetate (<em>P</em>=0.07). &nbsp;Statistically significant differences were observed in favour of letrozole 2.5 mg compared to megestrol acetate in overall objective tumour response rate (24% vs 16%, <em>P</em>=0.04), and in time to treatment failure (<em>P</em>=0.04). Overall survival was not significantly different between the 2 arms (<em>P</em>=0.2).</p><p>In the second study, the response rate was not significantly different between letrozole 2.5 mg and aminoglutethimide (<em>P</em>=0.06). Letrozole 2.5 mg was statistically superior to aminoglutethimide for time to progression (<em>P</em>=0.008), time to treatment failure (<em>P</em>=0.003) and overall survival (<em>P</em>=0.002).</p><p><u>Male</u><u> </u><u>breast</u><u> </u><u>cancer</u></p><p>Use of letrozole in men with breast cancer has not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Letrozole is rapidly and completely absorbed from the gastrointestinal tract (mean absolute bioavailability: 99.9%). Food slightly decreases the rate of absorption (median tmax&nbsp;1 hour fasted versus 2 hours fed; and mean Cmax&nbsp;129 &plusmn; 20.3 nmol/litre fasted versus 98.7 &plusmn; 18.6 nmol/litre fed) but the extent of absorption (AUC) is not changed. The minor effect on the absorption rate is not considered to be of clinical relevance, and therefore letrozole may be taken without regard to mealtimes.</p><p><u>Distribution</u></p><p>Plasma protein binding of letrozole is approximately 60%, mainly to albumin (55%). The concentration of letrozole in erythrocytes is about 80% of that in plasma. After administration of 2.5 mg 14C-labelled letrozole, approximately 82% of the radioactivity in plasma was unchanged compound. Systemic exposure to metabolites is therefore low. Letrozole is rapidly and extensively distributed to tissues. Its apparent volume of distribution at steady state is about 1.87 &plusmn; 0.47 l/kg.</p><p><u>Biotransformation</u></p><p>Metabolic clearance to a pharmacologically inactive carbinol metabolite is the major elimination pathway of letrozole (CLm&nbsp;= 2.1 l/h) but is relatively slow when compared to hepatic blood flow (about 90 l/h). The cytochrome P450 isoenzymes 3A4 and 2A6 were found to be capable of converting letrozole to this metabolite. Formation of minor unidentified metabolites and direct renal and faecal excretion play only a minor role in the overall elimination of letrozole. Within 2 weeks after administration of 2.5 mg 14C-labelled letrozole to healthy postmenopausal volunteers, 88.2 &plusmn; 7.6% of the radioactivity was recovered in urine and 3.8 &plusmn; 0.9% in faeces. At least 75% of the radioactivity recovered in urine up to 216 hours (84.7 &plusmn; 7.8% of the dose) was attributed to the glucuronide of the carbinol metabolite, about 9% to two unidentified metabolites, and 6% to unchanged letrozole.</p><p><u>Elimination</u></p><p>The apparent terminal elimination half-life in plasma is about 2 to 4 days. After daily administration of 2.5 mg steady- state levels are reached within 2 to 6 weeks. Plasma concentrations at steady state are approximately 7 times higher than concentrations measured after a single dose of 2.5 mg, while they are 1.5 to 2 times higher than the steady-state values predicted from the concentrations measured after a single dose, indicating a slight non-linearity in the pharmacokinetics of letrozole upon daily administration of 2.5 mg. Since steady-state levels are maintained over time, it can be concluded that no continuous accumulation of letrozole occurs.</p><p><u>Linearity/non-linearity</u></p><p>The pharmacokinetics of letrozole were dose proportional after single oral doses up to 10 mg (dose range: 0.01 to 30 mg) and after daily doses up to 1.0 mg (dose range: 0.1 to 5mg). After a 30 mg single oral dose there was a slightly dose over-proportional increase in AUC value. The dose over-proportionality is likely to be the result of a saturation of metabolic elimination processes. Steady levels were reached after 1 to 2 months at all dosage regimens tested (0.1-5.0 mg daily).</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>Age had no effect on the pharmacokinetics of letrozole.</p><p><em>Renal</em><em> </em><em>impairment</em></p><p>In a study involving 19 volunteers with varying degrees of renal function (24-hour creatinine clearance 9-116 ml/min) no effect on the pharmacokinetics of letrozole was found after a single dose of 2.5 mg. In addition to the above study assessing the influence of renal impairment on letrozole, a covariate analysis was performed on the data of two pivotal studies (Study AR/BC2 and Study AR/BC3). Calculated creatinine clearance (CLcr) [Study AR/BC2 range: 19 to 187 mL/min; Study AR/BC3 range: 10 to 180 mL/min] showed no statistically significant association between letrozole plasma trough levels at steady-state (Cmin). Futhermore, data of Study AR/BC2 and Study AR/BC3 in second-line metastatic breast cancer showed no evidence of an adverse effect of letrozole on CLcr or an impairment of renal function.</p><p>Therefore, no dose adjustment is required for patients with renal impairment (CLcr &ge;10 mL/min). Little information is available in patients with severe impairment of renal function (CLcr &lt;10 mL/min).</p><p><em>Hepatic</em><em> </em><em>impairment</em></p><p>In a similar study involving subjects with varying degrees of hepatic function, the mean AUC values of the volunteers with moderate hepatic impairment (Child-Pugh B) was 37% higher than in normal subjects, but still within the range seen in subjects without impaired function. In a study comparing the pharmacokinetics of letrozole after a single oral dose in eight male subjects with liver cirrhosis and severe hepatic impairment (Child-Pugh C) to those in healthy volunteers (N=8), AUC and t&frac12;&nbsp;increased by 95 and 187%, respectively. Thus, letrozole should be administered with caution to patients with severe hepatic impairment and after consideration of the risk/benefit in the individual patient.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a variety of preclinical safety studies conducted in standard animal species, there was no evidence of systemic or target organ toxicity.</p><p>Letrozole showed a low degree of acute toxicity in rodents exposed up to 2000 mg/kg. In dogs letrozole caused signs of moderate toxicity at 100 mg/kg.</p><p>In repeated-dose toxicity studies in rats and dogs up to 12 months, the main findings observed can be attributed to the pharmacological action of the compound. The no-adverse-effect level was 0.3 mg/kg in both species.</p><p>Oral administration of letrozole to female rats resulted in decreases in mating and pregnancy ratios and increases in pre- implantation loss.</p><p>Both <em>in vitro </em>and <em>in vivo </em>investigations of letrozole&#39;s mutagenic potential revealed no indications of any genotoxicity.</p><p>In a 104-week rat carcinogenicity study, no treatment-related tumours were noted in male rats. In female rats, a reduced incidence of benign and malignant mammary tumours at all the doses of letrozole was found.</p><p>In a 104-week mouse carcinogenicity study, no treatment-related tumors were noted in male mice. In female mice, a generally dose-related increase in the incidence of benign ovarian granulosa theca cell tumors was observed at all doses of letrozole tested. These tumors were considered to be related to the pharmacological inhibition of estrogen synthesis and may be due to increased LH resulting from the decrease in circulating estrogen.</p><p>Letrozole was embryotoxic and foetotoxic in pregnant rats and rabbits following oral administration at clinically relevant doses. In rats that had live foetuses, there was an increase in the incidence of foetal malformations including domed head and cervical/centrum vertebral fusion. An increased incidence of foetal malformations was not seen in the rabbit. It is not known whether this was an indirect consequence of the pharmacological properties (inhibition of oestrogen biosynthesis) or a direct drug effect (see sections 4.3 and 4.6).</p><p>Preclinical observations were confined to those associated with the recognised pharmacological action, which is the only safety concern for human use derived from animal studies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablets content: lactose monohydrate, sodium carboxymethyl starch, microcrystalline cellulose, hypromellose, anhydrous colloidal silica and magnesium stearate.</p><p>Coating: Opadry Yellow, are: hypromellose, macrogol 6000, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172) and tartrazine (E172).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PVDC/aluminium blisters.</p><p>Packs of 30 tablets (in 10 tablets blister-packs).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LABORATORIOS CINFA, S.A.

C/ Olaz-Chipi, 10. Polígono Industrial Areta

31620 Huarte (Navarra), Spain.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
13 October 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>